ReviewMolecular and cellular endocrinology2014
Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.
Review in Molecular and cellular endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 94 citations in OpenAlex.
- Current understanding of the role of DNA methylation in pituitary neuroendocrine tumors.Neuro-oncology advances · 2025Article
- A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.Cancers · 2025Review
- The evolution and application of multi-omic analysis for pituitary neuroendocrine tumors.Frontiers in medicine · 2025Review
- Pituitary Adenoma:Medicina (Kaunas, Lithuania) · 2024Article
- Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.CNS neuroscience & therapeutics · 2023Review
- Sprouting Angiogenesis in Human Pituitary Adenomas.Frontiers in oncology · 2022Article
- High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors.Frontiers in oncology · 2022Article
- Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.Acta neuropathologica communications · 2021Article
- Multiple endocrine neoplasia type 1 with a frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas: case report.BMC endocrine disorders · 2021Article
- Large Scale Molecular Studies of Pituitary Neuroendocrine Tumors: Novel Markers, Mechanisms and Translational Perspectives.Cancers · 2021Review
- Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.Frontiers in endocrinology · 2021Review
- Genetic and expression variations of cell cycle pathway genes in brain tumor patients.Bioscience reports · 2020Article
- Genetic and Epigenetic Causes of Pituitary Adenomas.Frontiers in endocrinology · 2020Review
- Histopathological classification of non-functioning pituitary neuroendocrine tumors.Pituitary · 2018Review
- Recent advances in understanding corticotroph pituitary tumor initiation and progression.F1000Research · 2018Review
- HMGA2 cooperates with either p27Cell cycle (Georgetown, Tex.) · 2018Article
- Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
- Expression and clinical significance of EGR-1 and PTEN in the pituitary tumors of elderly patients.Oncology letters · 2017Article
- Long non-coding RNA C5orf66-AS1 is downregulated in pituitary null cell adenomas and is associated with their invasiveness.Oncology reports · 2017Article
- Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas.Molecular and cellular endocrinology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Human pituitary adenomas are the most common intracranial neoplasms. Approximately 5% of them are familial adenomas. Patients with familial tumors carry germline mutations in predisposition genes, including AIP, MEN1 and PRKAR1A. These mutations are extremely rare in sporadic pituitary adenomas, which therefore are caused by different mechanisms. Multiple tumor suppressive genes linked to sporadic tumors have been identified. Their inactivation is caused by epigenetic mechanisms, mainly promoter hypermethylation, and can be placed into two groups based on their functional interaction with tumor suppressors RB or p53. The RB group includes CDKN2A, CDKN2B, CDKN2C, RB1, BMP4, CDH1, CDH13, GADD45B and GADD45G; AIP and MEN1 genes also belong to this group. The p53 group includes MEG3, MGMT, PLAGL1, RASSF1, RASSF3 and SOCS1. We propose that the tumor suppression function of these genes is mainly mediated by the RB and p53 pathways. We also discuss possible tumor suppression mechanisms for individual genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.